Event Details
Accelerating the Future of Cell and Gene Therapy in Boston
May 11–15, 2026 | Thomas M. Menino Convention & Exhibition Center | Boston, MA
Join Aldevron, a Danaher company, at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting.
Aldevron empowers genomic medicine pioneers with integrated, scalable solutions, including end-to-end gene editing solutions, plasmid DNA manufacturing, mRNA drug substance and drug product manufacturing.
Engage with our subject matter experts at booth #1337, or schedule a meeting with our team at ASGCT to discuss your program.
Schedule a Meeting
Meet with our team to discuss your cell and gene therapy programs, explore advanced solutions for plasmid DNA, mRNA drug substance and drug product, and end-to-end gene editing workflows.
Scientific Posters
Gain insight into Aldevron’s latest scientific advancements. Visit our team during poster sessions or join the evening receptions for in-depth conversations.
Engineering DNA Templates for Cell Specificity, Safety, and cGMP Scalability for In Vivo Gene Editing Therapeutics
Speaker: Dr. Tyler Kozisek
Date & Time: Wednesday, May 13, 5 - 6:30 pm
Location: Poster Hall
A Scalable RCA-Based Platform for Producing High-Quality Linear DNA Templates for IVT mRNA Production
Speaker: Nate Russart
Date & Time: Thursday, May 14, 5 - 6:30 pm
Location: Poster Hall
Poster hall open: May 11–14, evenings 5–6:30 pm; please refer to the ASGCT event schedule for updates.
Aldevron Knowledge Lab Sessions
Join our scientific team for highly focused sessions in room 213. In these sessions, we will highlight the latest advancements in the field of cell and gene therapy. Light lunch will be provided, and registration is limited on a first-come, first-served basis.
Not attending ASGCT? Register at the event page to receive a recording after the conference.
Advancing mRNA Manufacturing with Alchemy: Next Generation Cell-Free DNA Solutions for Speed, Quality, and Scalability
Speaker: Nate Russart
Date & Time: Tuesday, May 12, 12 – 1:15 pm
Location: Room 213
Learn about Aldevron’s Alchemy platform, delivering rapid, efficient, and high-fidelity cell-free template DNA solutions for next-generation mRNA therapeutics manufacturing.
From Design to Delivery: A Translational Framework for Non-Viral Gene Editing
Speakers: Max Sellman (Aldevron), Ashley Jacobi (Integrated DNA Technologies)
Date & Time: Wednesday, May 13, 12 – 1:15 pm
Location: Room 213
Explore a comprehensive workflow for non-viral CRISPR-mediated gene editing supporting both in vivo and ex vivo genomic medicine applications, with emphasis on specificity, manufacturability, and regulatory considerations.
Lunch Scientific Symposia: The Path from N=1 to N to Many Will Hinge on Manufacturing and Quality Innovation
How can the field responsibly and sustainably move from individualized breakthroughs like Baby KJ to broader access for genomic medicine? This session explores critical advances in manufacturing, quality, and regulatory systems that will enable personalized and CRISPR-enabled therapies to reach more patients.
Keynote: Dr. Kiran Musunuru, Barry J. Gertz Professor for Translational Research, University of Pennsylvania
Fireside Chat:
- Dr. Kiran Musunuru
- Dr. Patricia Musolino, Associate Professor of Neurology, Harvard Medical School
- Dr. Scott Ripley, VP and GM, Nucleic Acids and Nanomedicine, Cytiva
- Dr. Venkata Indurthi, CSO, Aldevron
Date & Time: Thursday, May 9, 2024, 12:00 PM - 1:30 PM ET
Location: Ballroom 4
Lunch will be provided. Seating is limited and available on a first-come, first-served basis.
Aldevron Solutions at a Glance
Gene Editing:
Access a complete suite of gene editing tools and services, including custom and catalog CRISPR nucleases, GMP-Grade guide RNA, and Nanoplasmid™ DNA for ex vivo and in vivo programs.
Explore Gene Editing Solutions
mRNA Therapeutics:
Leverage our industry-leading mRNA synthesis and manufacturing solutions, including our new Alchemy™ platform, integrating advanced cell-free DNA templates for the scale-up of vaccines and therapeutics.
Gene-Modified Cell Therapy (GMCT):
Utilize our comprehensive plasmid DNA solutions to support viral and non-viral cell therapy development, from early research through clinical and commercial manufacturing.